옵션 체인은 다양한 행사가격과 만기일에 대한 Certara의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Certara에 대한 시장 심리를 평가합니다..

Certara (NASDAQ:CERT) 주식, 옵션 체인

Certara

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.

Las,Vegas,,Usa,-,April,13,,2014:,Hertz,Car,Rental

Equities

Mid Cap

News

Movers

BULL

CERT

MTSR

SBSW

VIST

ZLAB

허츠, 비스타 에너지 등 지난주 급등한 중형주 6종목 (4월 14~18일)

AerovironmentRichmond,,Virginia,,Usa,-,8,May,2019:,Illustrative,Editorial,Of

Trading Ideas

AVAV

LOAR

ORLA

RXRX

RYTM

STRL

리커전·아이엠골드 등 지난주 시장 변동성 속 급등한 중형주 11종목 (4월 7일~11일) 지난주 최고의 성과를 올린 중형주는 다음과 같다.

리커전·아이엠골드 등 지난주 시장 변동성 속 급등한 중형주 11종목 (4월 7일~11일)

Silver,Spring,,Md,,Usa,-,June,25,,2022:,The,Fda

Biotech

Government

Regulations

Health Care

After-Hours Center

ABSI

SDGR

미국 식품의약국(FDA)이 동물실험 의무 조항을 단계적으로 폐지할 계획을 발표했다. 이에 목요일(10일) 장 마감 후 헬스케어 기술 분야의 여러 주식이 상승세를 보이고 있다.

美FDA, 동물실험 의무 조항 단계적 폐지 발표...헬스케어 기술 주식 급등

Certara Inc

CertiK

CERTIVE SOLUTIONS INC by Certive Solutions, Inc.

Certive Solutions Inc

Defiance ETFs has launched the PLTZ ETF, the <a href="https://www.benzinga.com/etfs">first leveraged inverse fund</a> to focus on Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), providing short sellers with a new means to double down, literally, on short-term dips in the contentious software company. 
The Defiance Daily Target 2X Short PLTR ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTZ#NASDAQ">PLTZ</a>) aims for daily returns that are -200% the price movement of Palantir&#8217;s stock. The introduction adds fuel to the increasing single-stock ETF craze, but with a twist: rather than following trends, PLTZ is about shorting them.
Also Read:<a href="https://www.benzinga.com/etfs/new-etfs/25/06/45819073/seeking-income-and-stability-neoss-gold-high-income-etf-may-be-your-answer"> Seeking Income And Stability? NEOS&#8217;s Gold High Income ETF May Be Your Answer</a>
This is at a particularly charged moment for Palantir. The New York Times reported last week that the company was commissioned by the Trump administration to gather information on Americans in the wake of a March executive order encouraging inter-agency data sharing. 
Despite <a href="https://www.benzinga.com/markets/tech/25/06/45800099/palantir-ceo-alex-karp-refutes-ridiculous-surveillance-reports-says-company-is-winning">Palantir CEO Alex Karp labeling the report &#8220;ridiculous&#8221;</a> and technically unsound on CNBC, the political firestorm surrounding the company has reignited again, possibly making PLTZ more attractive to short-term traders sensing smoke.
Karp wasn&#8217;t shy, telling CNBC&#8217;s Squawk on the Street that if someone &#8220;wanted to use the Deep State to unlawfully surveil people, the last platform in the world you would pick is Palantir,&#8221; and asserted even a low-level engineer could discredit the NYT article in less than two minutes.
Meanwhile, <a href="https://www.benzinga.com/news/contracts/25/05/45702431/palantir-stock-gains-as-trump-expands-companys-role-in-us-government-agencies">Palantir has inked fresh deals</a> with the Department of Homeland Security and the Pentagon, and is reportedly in talks with other powerful U.S. agencies including the IRS and the Social Security Administration. Whether that's a testament to the company's dominance, or a red flag for data centralization, may depend on which side of the Palantir trade you're on.
For tactical traders who are active, <a href="https://www.globenewswire.com/news-release/2025/06/06/3094873/0/en/Defiance-Launches-PLTZ-The-First-2X-Short-ETF-for-Palantir-Technologies-Inc.html">PLTZ </a>provides an option to be bearish on Palantir stock without tampering with margin calls or struggling with exotic options. But as with any levered ETF, particularly a short one, timing is everything, and risk appetite must be greater than Karp&#8217;s blood pressure after the interview.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/06/45818985/koid-etf-your-gateway-to-the-5-trillion-humanoid-robotics-market">KOID ETF: Your Gateway To The $5 Trillion Humanoid Robotics Market</a></li>
</ul>
Photo: Spyro the Dragon/Shutterstock

New ETFs

ETFs

PLTR

PLTZ

Defiance's New PLTZ ETF Lets You Double Down On A Drop in Palantir Stock

WIIM

CNCK

DAVE

DOMH

ERIE

EWBC

GSIW

HIPO

HOOD

IBKR

ILLR

JFIN

KSPI

LMND

LPLA

NCPL

OXBR

ROOT

SOFI

UPST

Shares of financial companies are trading higher, supported by broad market strength, after better-than-expected nonfarm payrolls data eased concerns about an imminent economic slowdown.

<a href="https://x.com/solidiontech/status/1931073546911875256">https://x.com/solidiontech/status/1931073546911875256</a>
&nbsp;

Solidion Technology Posts On X "$STI Bitcoin corporate treasury strategy networking at @TheBitcoinConf last week"; Shares See Volume To The Upside

ACHR

EVTL

JOBY

Shares of electric air taxi companies are trading higher after the White House announced that President Trump signed an executive order to advance electric air taxis and enable expanded drone operations.

<h3 class="wp-block-heading">New On The Block</h3>
Byron Allen's Allen Media Group has hired Moelis &amp; Company to explore a sale of its TV stations across 21 markets. The company spent over $1 billion acquiring Big Four network affiliates (ABC, NBC, CBS, FOX) over the past six years. 
It is now looking to cash out and reduce debt. Deadline <a href="https://deadline.com/2025/06/allen-media-group-hires-investment-bank-to-sell-tv-stations-1236420381/">reported</a> that the TV stations have received multiple offers. 
Also for sale: 
<ul class="wp-block-list">
<li>Jefferies is shopping around PatientPoint, a health marketing and ad agency, according <a href="https://www.axios.com/pro/health-tech-deals/2025/06/04/patientpoint-jefferies-sale">to</a> Axios. L Catterton, Littlejohn &amp; Co. and Transformation Capital are on the sell side. </li>
<li>Just three years ago, private equity firm One Equity Partners <a href="https://www.oneequity.com/news/one-equity-partners-completes-investment-in-infucare-rx-a-leading-home-infusion-therapy-provider/">completed</a> a strategic investment in infusion provider InfuCare. Today? It&#8217;s looking to get rid of it. According to Axios, JPMorgan is <a href="https://www.axios.com/pro/health-tech-deals/2025/06/03/infucare-one-equity-jpmorgan-sale">looking</a> for a buyer. </li>
<li>Swiss biotech MoonLake Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) received a <a href="https://www.benzinga.com/news/health-care/25/06/45743008/mercks-dealmaking-intensifies-with-moonlake-bid-as-keytruda-patent-cliff-nears-report">bid exceeding $3 billion</a> from Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>). MoonLake turned down the initial offer, but talks are reportedly revived. The potential purchase signals renewed dealmaking activity as investor pressure has mounted on Merck to secure new assets, especially as its blockbuster <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">cancer drug Keytruda</a> faces patent expiration as early as 2028.</li>
</ul>
<h3 class="wp-block-heading">Updates From The Block</h3>
<ul class="wp-block-list">
<li>Post Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POST#NYSE">POST</a>) is forking over $880 million—including assumed debt—to buy 8th Avenue Food &amp; Provisions. That means brands like Ronzoni pasta will go back into Post&#8217;s pantry. <a href="https://www.wsj.com/articles/post-holdings-to-buy-ronzoni-pasta-owner-8th-avenue-food-cf8f454c?mod=deals_news_article_pos2">Per</a> The Wall Street Journal, the private-label brands originally got spun off into 8th Avenue in 2018 with help from private equity firm THL. Post plans to wipe out 8th Avenue's net debt and pick up the tab for all equity interests, including $111 million in finance leases. All in, the transaction is expected to cook up $15 million in annual synergies by the end of fiscal 2026. If Post closes by July 1, it expects 2026 to be more profitable (on an adjusted basis) than initially expected.</li>
</ul>
<ul class="wp-block-list">
<li>Rosebank Industries (LON: ROSE) is once again in talks to buy Electrical Components International (ECI), a wire harnesses manufacturer, for about $1.9 billion, Reuters reported. Rosebank was in talks to buy ECI in February but dropped the plans in March.</li>
</ul>
<ul class="wp-block-list">
<li>Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) agreed to acquire Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.S. and the EU. The acquisition will also include elenestinib, a next-generation medicine for SM, and BLU-808, a highly selective and potent oral wild-type KIT inhibitor with the potential for immunology diseases. Sanofi will pay&nbsp;$129&nbsp;per share in cash, representing an equity value <a href="https://www.benzinga.com/news/health-care/25/06/45719179/sanofi-expands-rare-immunology-portfolio-with-blueprint-buyout">of roughly&nbsp;$9.1 billion</a>.</li>
</ul>
<ul class="wp-block-list">
<li>Suzano S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUZ#NYSE">SUZ</a>) is acquiring a 51% stake in a new $3.4 billion tissue products joint venture with Kimberly-Clark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NASDAQ">KMB</a>), <a href="https://www.benzinga.com/m-a/25/06/45797473/tissue-titans-unite-suzano-kimberly-clark-form-3-4-billion-global-jv">paying $1.734 billion in cash</a>. Kimberly-Clark will retain a 49% stake. The Netherlands-based venture will produce and distribute toilet paper and facial tissues in 70 countries, with 22 factories across 14 countries, employing about 9,000 people. The facilities have an annual capacity of 1 million tonnes and generated $3.3 billion in net sales in 2024.</li>
</ul>
<h3 class="wp-block-heading">Off The Block</h3>
<ul class="wp-block-list">
<li>Robinhood (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45740112/robinhood-completes-200-million-bitstamp-deal-gains-access-to-500k-crypto-users-and-95-million-revenue-stream">completed its $200 million acquisition</a> of Bitstamp, a crypto exchange that had raised around $40 million from firms like Pantera Capital and Ripple.</li>
</ul>
<ul class="wp-block-list">
<li>Cactus Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHD#NYSE">WHD</a>) <a href="https://www.benzinga.com/m-a/25/06/45724879/cactus-takes-majority-stake-in-baker-hughes-spc-for-global-reach">formed a joint venture</a> with Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>), taking a 65% stake and operational control of Baker Hughes&#8217; Surface Pressure Control (SPC) business. Baker Hughes will retain a 35% stake. The new venture, separate from Cactus' current pressure control unit, will focus on international wellhead and production tree systems.</li>
</ul>
<ul class="wp-block-list">
<li>Guardian Pharmacy Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>) is <a href="https://www.benzinga.com/pressreleases/25/06/b45719054/guardian-pharmacy-services-expands-pacific-northwest-footprint-with-acquisition-of-washington-base" target="_blank" rel="noreferrer noopener">entering the Pacific Northwest market</a> via acquisition. Mercury Pharmacy Services, a provider of long-term care pharmacy solutions, agreed to a price, but <a href="https://www.benzinga.com/m-a/25/06/45723960/guardian-pharmacy-strengthens-us-footprint-with-new-seattle-area-acquisition">the amount remains undisclosed</a>.</li>
</ul>
<h3 class="wp-block-heading">Bankruptcy Block</h3>
<ul class="wp-block-list">
<li>AI startup Builder.ai has filed for Chapter 7 bankruptcy in Delaware after creditors seized most of its cash, citing overstated 2024 sales projections—by a staggering 300%. Once valued at $1.5 billion, Builder.ai is now the biggest AI collapse since the ChatGPT-driven investment boom began. According <a href="https://www.bloomberg.com/news/articles/2025-06-05/builder-ai-files-for-bankruptcy-after-creditors-seize-accounts?sref=TBDibEcD">to</a> Bloomberg, the fallout was fueled by revelations that Builder.ai allegedly faked business with Indian social media firm VerSe Innovation to inflate revenues. VerSe co-founder Umang Bedi denies any wrongdoing, calling the claims "baseless and false."</li>
</ul>
<ul class="wp-block-list">
<li>Hooters closed some 30 corporate-owned restaurants and explained that it has <a href="https://www.businesswire.com/news/home/20250331979797/en/Hooters-of-America-Takes-Strategic-Action-to-Continue-its-Iconic-Legacy-Under-Pure-Franchise-Business-Model" target="_blank" rel="noreferrer noopener">no plans </a>to shut down any other locations. The Atlanta, Georgia-based restaurant chain went <a href="https://www.benzinga.com/personal-finance/25/04/44647084/hooters-files-for-bankruptcy-says-brand-isnt-going-anywhere">bankrupt earlier this year</a>.</li>
</ul>
<ul class="wp-block-list">
<li>Alex Jones may see his personal assets — including guns, cars, and homes — sold by the end of the year, according to the Houston Chronicle, <a href="https://www.houstonchronicle.com/news/houston-texas/texas/article/alex-jones-personal-assets-sales-bankruptcy-20361565.php">citing</a> a bankruptcy trustee. The potential sale would mark the nearing end of his two-and-a-half-year bankruptcy process. Jones, who created the far-right conspiracy theory website Infowars, filed for bankruptcy in 2022 after being ordered to pay nearly $1.5 billion to families of Sandy Hook shooting victims for defamation.</li>
</ul>
<h3 class="wp-block-heading">Notes From The Block</h3>
A studio's IP portfolio and game development pipeline are critical for video game investors. A major acquirer in the sector is GDEV Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEV#NASDAQ">GDEV</a>). The Cyprus-based company has made three M&amp;A deals and spent $100 million on studio acquisitions since 2022. 
This week, Andrey Fadeev drafted <a href="https://www.benzinga.com/m-a/25/06/45722621/gdevs-founder-ceo-evaluates-m-a-deals-using-these-5-metrics">a listicle of key metrics</a> GDEV uses for M&amp;A evaluation.
<ol class="wp-block-list">
<li>LTV/CAC Ratio – Measures how efficiently a studio converts user acquisition spend into revenue. A ratio above 1.0 indicates profitable user growth.</li>
<li>Retention Rates (D1, D7, D30) – Track user engagement over time. High retention signals strong gameplay and monetization potential. Benchmarks vary by genre.</li>
<li>ARPU/ARPPU – Indicate monetization efficiency. ARPU includes all users; ARPPU focuses on paying users. Higher ARPU justifies higher CAC.</li>
<li>DAU/MAU Ratio – Shows user engagement depth. A ratio above 20% is considered strong.</li>
<li>EBITDA – Reflects core operational profitability and financial health. High EBITDA margins show sustainable growth and efficiency.</li>
</ol>
In 2024, video game M&amp;A activity reached $27.3 billion, underscoring the sector's immense growth and investment appeal. C-suite executives would be wise to consider these metrics when searching for their next target. 
<a href="https://www.benzinga.com/markets/asset-sales/25/05/45702349/deal-dispatch-beauty-brand-behavioral-health-firms-hit-auction-block">For last week&#8217;s edition of Deal Dispatch, click here</a>.
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/06/45816311/conagra-sells-seafood-brands-for-55m-as-it-sharpens-focus-on-core-business">Conagra Sells Seafood Brands For $55M As It Sharpens Focus On Core Business</a></li>
</ul>
Image created using a photo from Shutterstock.

Asset Sales

BPMC

GDEV

GRDN

KEYS

MLTX

POST

ROSE

SNOW

Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta

In May, the U.S. District Court for the District of Delaware ruled in favor of ACADIA Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) regarding its ‘721 formulation patent for Nuplazid (pimavanserin), Acadia&#8217;s drug for the treatment of <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">Parkinson&#8217;s Disease Psychosis</a>.
In order, the court ruled in favor of Acadia on infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other ANDA (Abbreviated New <a href="https://www.benzinga.com/pressreleases/25/05/b45474227/delaware-district-court-rules-in-favor-of-acadia-in-nuplazid-pimavanserin-formulation-patent-litig" target="_blank" rel="noreferrer noopener">Drug Application) filers</a>.
&#8220;We are very pleased with today&#8217;s decisive ruling in our favor, which provides patent protection for NUPLAZID 34 mg capsule formulation into 2038,&#8221; said CEO Catherine Owen Adams.
JPMorgan sees the ruling as &#8220;as a clear positive.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/05/45476079/acadia-pharmaceuticals-acad-stock-explodes-26-after-patent-court-victory" rel="noreferrer noopener">Acadia Pharmaceuticals (ACAD) Stock Explodes 26% After Patent Court Victory</a>
Analyst Tessa T Romero writes, &#8220;We believe it is logical to assume the parties would appeal the ruling, a process that could take ~1-2 years from start to finish.&#8221;
JPMorgan on Friday increased the price target from $26 to $30, reiterating <a href="https://www.benzinga.com/quote/ACAD/analyst-ratings" target="_blank" rel="noreferrer noopener">the Overweight rating</a>.
The analyst also notes the appeal in the composition of matter (COM) patent litigation at the U.S. Court of Appeals for the Federal Circuit is scheduled for June 6. The patent at issue is the ‘740 COM patent, which covers pimavanserin and salts thereof into 2030, including a patent term extension approved by the U.S. Patent and Trademark Office.
The JPMorgan analyst is confident that the U.S. Court of Appeals will favor Acadia on the ‘740 patent case. The analyst points to three reasons:
<ul class="wp-block-list">
<li>In December 2023, a lower court ruled in Acadia&#8217;s favor, confirming the patent&#8217;s validity.</li>
<li>A similar case involving Allergan also ended positively, which supports Acadia&#8217;s position.</li>
<li>Legal experts consulted by JPMorgan believe there&#8217;s a 95% chance the ruling will go Acadia&#8217;s way.</li>
</ul>
The increased price target is based on the analyst&#8217;s conviction around a favorable outcome from the U.S. Court of Appeals for the Federal Circuit on the ‘740 patent.
Analyst Romero extended Nuplazid LOE assumption to 2038 from 2030 and, at the same time, accounted for potential headwinds from price negotiations under the IRA in the outer years as well as potential competitive threats from certain generic entrants, which could become available following the expiry of Nuplazid&#8217;s COM patent in 2030.
ACAD Price Action: ACADIA stock is up 2.18% at $21.81 at publication on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/legal/25/06/45797712/moderna-beats-alnylam-appeal-in-covid-vaccine-patent-case" target="_blank" rel="noreferrer noopener">Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case</a></li>
</ul>
Photo: Piotr Swat via Shutterstock

Analyst Color

Large Cap

Price Target

Analyst Ratings

General

ACAD

JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory

Abacus Global Management Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) shares are trading higher Friday after the company announced a $20 million share repurchase program and disclosed insider <a href="https://www.benzinga.com/pressreleases/25/06/g45821199/abacus-global-management-announces-share-repurchase-program-insider-buying">buying totaling over $2 million. </a>
What To Know: The buyback authorization is effective immediately and will remain in place for up to 18 months.
The move comes in response to what Abacus described as a recent short attack that it claims has artificially depressed its stock price. CEO Jay Jackson said the company sees this as a buying opportunity and emphasized that the board and employees are backing that view through both the repurchase plan and personal investments in the stock.
Abacus stated that it would use cash on hand and future free cash flow to fund the share repurchases. The company also noted that the timing and method of purchases will vary, potentially including open market buys, block trades, and negotiated deals.
In addition to financial action, the company said it is pursuing legal remedies against parties it accuses of spreading false and misleading information. The statement framed the repurchase and insider buying as a signal of confidence in the company&#8217;s long-term performance and stability. Investors responded positively to the news, pushing the stock higher during the session.
ABL Price Action: Abacus shares were up 7.34% at $6.14 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/45820223/stocks-rally-on-strong-jobs-numbers-tesla-rebounds-as-trump-musk-feud-softens-whats-driving-markets-friday">Stocks Rally On Strong Jobs Numbers; Tesla Rebounds As Trump-Musk Feud Softens: What&#8217;s Driving Markets Friday? </a></li>
</ul>
Image Via Shutterstock.

Abacus Global Management Shares Jump After Announcing Buyback Plan And Insider Purchases

Sen. Bernie Sanders (I-VT) and billionaire Elon Musk don't agree on much. But this week, they found common ground in their fierce opposition to President Donald Trump's latest tax and spending bill.
<h2 class="wp-block-heading">Bipartisan Outrage Over GOP&#8217;s &#8216;Big, Beautiful Bill&#8217;</h2>
On June 3, Musk <a href="https://x.com/elonmusk/status/1929954109689606359">posted</a> on X, calling the bill a &#8220;disgusting abomination&#8221; and slammed it for adding to the U.S. budget deficit. &#8220;This massive, outrageous, pork-filled Congressional spending bill is a disgusting abomination,&#8221; he wrote. &#8220;Shame on those who voted for it: you know you did wrong.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Musk is right: this bill IS a "disgusting abomination". We shouldn't give $664 billion in tax breaks to the 1%. We shouldn't throw 13.7 million people off of Medicaid. We shouldn't cut $290 billion from programs to feed the hungry. Let's defeat this disgusting abomination. <a href="https://t.co/Hg01E9xcB8">pic.twitter.com/Hg01E9xcB8</a>
&mdash; Bernie Sanders (@BernieSanders) <a href="https://twitter.com/BernieSanders/status/1929965591705649615?ref_src=twsrc%5Etfw">June 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
Sanders quickly echoed the sentiment. &#8220;Musk is right: this bill IS a &#8216;disgusting abomination&#8217;,&#8221; he <a href="https://x.com/BernieSanders/status/1929965591705649615">posted</a>. &#8220;We shouldn't give $664 billion in tax breaks to the 1%. We shouldn't throw 13.7 million people off of Medicaid. We shouldn't cut $290 billion from programs to feed the hungry. Let's defeat this disgusting abomination.&#8221;
The bill in question is a central component of Trump&#8217;s second-term agenda and was passed by the House last month. It extends tax cuts from his first term, boosts defense spending, phases out <a href="https://www.benzinga.com/markets/equities/25/05/45366272/republicans-target-ev-perks-with-new-bill-ford-tesla-rivian-face-fallout-as-200-billion-in-battery-belt-investments-hang-in-balance">electric vehicle subsidies</a>, and <a href="https://www.benzinga.com/news/25/06/45740803/elizabeth-warren-agrees-with-trump-on-scrapping-debt-limit-but-blasts-4-trillion-hike-for-billionair">raises the debt ceiling by $4 trillion</a>. It&#8217;s now in the hands of the Senate, where <a href="https://www.benzinga.com/news/25/05/45634863/gop-senators-threaten-to-block-trumps-tax-and-spending-bill-over-deficit-medicaid-cuts-and-debt-ceil">divisions are growing</a>.
When asked about Musk&#8217;s comments about the bill, White House press secretary Karoline Leavitt <a href="https://www.benzinga.com/news/politics/25/06/45764422/white-house-says-trump-is-sticking-to-the-big-beautiful-bill-despite-elon-musks-sharp-criticism-it-doesnt-change-the-presidents-opinion">defended the proposal</a>, saying that &#8220;the president already knows where Elon Musk stood on this bill.&#8221;
Trending: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
<h2 class="wp-block-heading">&#8216;With All Due Respect&#8217;</h2>
House Speaker Mike Johnson expressed disappointment over Musk's criticism, despite a 20-minute call the two had just the day before. &#8220;With all due respect, my friend Elon is terribly wrong about the one big beautiful bill,&#8221; Johnson <a href="https://www.youtube.com/watch?v=5R8NbUVnOtc">told</a> reporters. He said Musk had understood the bill&#8217;s merits during their conversation and added, &#8220;I just deeply regret that he's made this mistake.&#8221;
Johnson insisted the legislation reflects conservative priorities and emphasized that it would make Trump-era tax cuts permanent and slash government spending by $1.6 trillion, which he called &#8220;the most amount of money that any government has ever saved on planet Earth in a piece of legislation ever.&#8221;
But critics across the spectrum say the bill would result in massive deficits and harm lower-income Americans. Musk <a href="https://x.com/elonmusk/status/1929955052527202503">warned</a> it would raise the budget shortfall to $2.5 trillion and burden citizens with &#8220;crushingly unsustainable debt.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">It will massively increase the already gigantic budget deficit to $2.5 trillion (!!!) and burden America citizens with crushingly unsustainable debt <a href="https://t.co/dHCj3pprJO">https://t.co/dHCj3pprJO</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1929955052527202503?ref_src=twsrc%5Etfw">June 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?
The bill has exposed fractures in the Republican Party. Sen. Rand Paul (R-KY) said he <a href="https://www.benzinga.com/news/25/05/45634863/gop-senators-threaten-to-block-trumps-tax-and-spending-bill-over-deficit-medicaid-cuts-and-debt-ceil">won't support</a> any legislation that raises the debt ceiling. Trump, in response, called Paul's ideas &#8220;actually crazy&#8221; on <a href="https://truthsocial.com/@realDonaldTrump/posts/114619648032728687">Truth Social</a>.
Musk's break with Trump is especially notable given their recent collaboration. Until last week, Musk worked with the administration&#8217;s Department of Government Efficiency. He had praised parts of Trump's agenda before, and the president had lauded Musk's contributions, <a href="https://truthsocial.com/@realDonaldTrump/posts/114593895018014960">writing</a>, &#8220;he will, always, be with us.&#8221;
The alliance now appears to be straining. Musk hinted at political retaliation, <a href="https://x.com/elonmusk/status/1929984535456035202">writing</a>, &#8220;In November next year, we fire all politicians who betrayed the American people.&#8221;
Read Next:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>
Image: Shutterstock

Bernie Sanders And Elon Musk Unlikely Agree On One Thing: Trump's Tax Bill Is A 'Disgusting Abomination'—'Let's Defeat This'

SoFi Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) shares jumped 4.86% to $14.28 on Friday, building on Thursday's gain following a bullish <a href="https://www.williamblair.com/News/William-Blair-Hosts-45th-Annual-Growth-Stock-Conference">presentation</a> at the 45th Annual William Blair Growth Stock Conference. Shares have now risen 7.45% since Monday's open.
What To Know: During the event, SoFi CFO Chris Lapointe <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45802964/sofi-technologies-stock-climbs-as-company-touts-strong-growth-at-investor-conference">highlighted</a> the company's expanding footprint, with 11 million members and over 15 million products. 
He outlined ambitious targets, including over $3 billion in adjusted net revenue by 2025 and adjusted EBITDA between $875 million and $895 million. That outlook supports a long-term plan for 25%+ annual revenue growth through 2026.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45819381/plug-power-stock-surges-13-whats-going-on">Plug Power Stock Surges 13%: What&#8217;s Going On?</a>
Key growth drivers include a strong loan origination business, $1.6 billion in first-quarter 2025, and $27 billion in deposits fueling its SoFi Money platform. Fee-based income now accounts for 41% of revenue, while a rebound in student loan refinancing adds further upside.
Broader markets also <a href="https://www.benzinga.com/markets/economic-data/25/06/45820223/stocks-rally-on-strong-jobs-numbers-tesla-rebounds-as-trump-musk-feud-softens-whats-driving-markets-friday">rallied</a> Friday as May jobs data beat expectations, easing slowdown fears. Nonfarm payrolls grew by 139,000, above forecasts, while the unemployment rate held at 4.2%.
Read Also: <a href="https://www.benzinga.com/markets/economic-data/25/06/45820223/stocks-rally-on-strong-jobs-numbers-tesla-rebounds-as-trump-musk-feud-softens-whats-driving-markets-friday">Stocks Rally On Strong Jobs Numbers; Tesla Rebounds As Trump-Musk Feud Softens: What&#8217;s Driving Markets Friday?</a>
<h2 class="wp-block-heading">How To Buy SOFI Stock</h2>
By now you're likely curious about how to participate in the market for SoFi Technologies &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SOFI has a 52-week high of $18.42 and a 52-week low of $6.01.
Image: Shutterstock

SoFi Technologies Stock Surges As Growth Outlook Impresses: What's Going On?

President Trump Signs Executive Order To Bolster U.S. Airspace Security Against Potential Threats From Drones; Trump Signs Order To Advance Electric Air Taxis, Allow For Advanced Drone Operations; Trump Signs Order Directing Federal Aviation Administration To Lift U.S. Ban On Civil Supersonic Aircraft Flight Over Land

Phathom Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) shares are trading higher Friday after the company <a href="https://www.benzinga.com/pressreleases/25/06/g45819139/phathom-pharmaceuticals-announces-positive-fda-decision-to-recognize-10-years-of-regulatory-exclus">announced a major regulatory win. </a>
What To Know: The FDA has granted 10-year new chemical entity exclusivity for its drug Voquezna, extending full market protection through May 3 2032. The FDA also updated the Orange Book listings for the 10 mg and 20 mg Voquezna tablets to reflect this extended exclusivity.
This move came in response to a citizen petition from Phathom arguing that Voquezna, which contains the same active moiety vonoprazan as the previously approved Voquezna Triple Pak and Dual Pak, qualifies for the same new chemical entity plus GAIN Act-based exclusivity period. The Voquezna Paks had previously been granted Qualified Infectious Disease Product designation and received a total of 10 years of exclusivity under the FDA's umbrella policy. That policy allows later products containing the same new active moiety to benefit from the same exclusivity period, even if those later products aren't independently designated as Qualified Infectious Disease Products.
The FDA reviewed the petition and agreed with Phathom's interpretation, concluding that the 10-year NCE+GAIN exclusivity granted to the Voquezna Paks must also apply to Voquezna. The agency cited longstanding legal and regulatory precedent supporting its decision and committed to updating the Orange Book accordingly.
Investors responded strongly to the news, as the 10-year exclusivity effectively blocks generic competition until 2032. The ruling secures Phathom's market position for Voquezna and enhances the commercial value of the drug. The move in the stock reflects renewed confidence in the company's long-term revenue prospects tied to its acid-suppressing product line.
PHAT Price Action: Phathom shares were down 95.0% at $9.16 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/45820223/stocks-rally-on-strong-jobs-numbers-tesla-rebounds-as-trump-musk-feud-softens-whats-driving-markets-friday">Stocks Rally On Strong Jobs Numbers; Tesla Rebounds As Trump-Musk Feud Softens: What&#8217;s Driving Markets Friday? </a></li>
</ul>
Image Via Shutterstock.

PHAT

Phathom Pharmaceuticals Stock Doubles After FDA Grants Full 10-Year Exclusivity For Voquezna

Shares of ProShares UltraPro QQQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TQQQ#NASDAQ">TQQQ</a>) surged 3.24% to $74.48 Friday afternoon as investors cheered stronger-than-expected <a href="https://www.benzinga.com/markets/economic-data/25/06/45820223/stocks-rally-on-strong-jobs-numbers-tesla-rebounds-as-trump-musk-feud-softens-whats-driving-markets-friday">U.S. labor data</a> and a broad rally in tech stocks.
What To Know: TQQQ is a leveraged ETF designed to deliver three times the daily performance of the Nasdaq-100 Index, making it especially sensitive to movements in high-growth tech names.
May&#8217;s nonfarm payrolls <a href="https://www.benzinga.com/markets/economic-data/25/06/45812372/us-labor-markets-defies-tariff-concerns-as-nonfarm-payrolls-wages-top-expectations-in-may">increased</a> by 139,000, topping economist forecasts of 130,000, while average hourly earnings rose 0.4%, the fastest monthly gain since January. The unemployment rate held steady at 4.2%. The robust data eased concerns about an economic slowdown and boosted confidence in consumer spending.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45819381/plug-power-stock-surges-13-whats-going-on">Plug Power Stock Surges 13%: What&#8217;s Going On?</a>
The Nasdaq-100 jumped 1% on the session, lifting TQQQ alongside it. Tech stocks led gains, with Tesla rebounding more than 5% following Thursday's steep drop. Market sentiment also improved after the White House downplayed tensions between Elon Musk and President Donald Trump.
Rising Treasury yields and a stronger dollar reflected expectations for continued economic strength, but it was the renewed momentum in large-cap tech that drove TQQQ's sharp advance. With the Nasdaq-100 nearing record highs, leveraged ETFs like TQQQ are benefiting from bullish bets on tech outperformance.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45820264/top-2-alternatives-to-tesla-after-the-musk-trump-breakup">Top 2 Alternatives To Tesla After The Musk-Trump Breakup</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TQQQ has a 52-week high of $93.78 and a 52-week low of $35.00.

TQQQ

ProShares UltraPro QQQ (TQQQ) Trades Higher On Strong Jobs Data, Tech Rally

CLYM

Climb Bio shares are trading higher after Oppenheimer initiated its coverage on the stock with a Outperform rating and announced a price target of $10.

Wall Street analysts responded to Ciena Corp.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) second-quarter financial results on Thursday.
Ciena reported a <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45790736/ciena-stock-slides-after-q2-eps-miss-margin-drop-despite-strong-sales" rel="noreferrer noopener">quarterly revenue growth</a> of 23.6% to $1.13 billion, beating the&nbsp;analyst consensus&nbsp;estimate of $1.09 billion.
The American telecommunications networking equipment and software services supplier reported an adjusted EPS of 42 cents,&nbsp;which missed the&nbsp;analyst consensus estimate&nbsp;of 52 cents.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45779192/ciena-ai-ambitions-face-margin-math-marvell-ous-analyst" rel="noreferrer noopener">Ciena Set To Beat Q2 Estimates But AI Ambitions Face Margin Math And Marvell-ous Rivals</a>
The adjusted gross margin declined by 250 bps to 41%, and the adjusted operating margin increased by 140 bps to 8.2%.
Rosenblatt analyst Mike Genovese maintained Ciena <a href="https://www.benzinga.com/quote/CIEN/analyst-ratings" target="_blank" rel="noreferrer noopener">with a Neutral</a> and lowered the price target from&nbsp;$85&nbsp;to&nbsp;$78.
Needham analyst Ryan Koontz reiterated Ciena with a Buy and a $90&nbsp;price target.
Rosenblatt: Genovese noted his Ciena preview was accurate since he expected increased revenue guidance. However, he was worried about margins because of customer and product mix and the time it could take to achieve the mid-40s gross margin and mid-teens operating margin targets.
The analyst said the gross margin was light because of a heavy sales mix of new line systems, which tend to get filled with high-margin cards later and 400ZR pluggable. The good news is that higher revenues appear sustainable.
Genovese said Cloud and Service Provider DCI markets can drive multi-year growth above 8% to 11%. The analyst noted Ciena will likely increase its multi-year revenue growth above this range before the end of fiscal 2025. He said the company has also won its first two Datacom Campus deals, including one likely to be worth hundreds of millions of dollars, with revenues slated to begin in 2026.
As per Genovese, the read for Datacom companies, like Lumentum Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) and Coherent Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>), is positive since Cloud capex is substantial and the 1.6+T Datacom products Ciena is moving over the next few years are expected to be good for the gross margins. 
The read is also positive for Telecom- and DCI-exposed names, like Viavi Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>), Ribbon Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>) and ADTRAN Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTN#NASDAQ">ADTN</a>), since Telecom demand is strong and Ciena&#8217;s gross margins issues are company-specific, the analyst said.
For Ciena, he sought signs that margins are sustainably improving before potentially becoming more constructive in his rating.
Genovese projected fiscal 2025 revenue of $4.58 billion (prior $4.41 billion) and adjusted EPS of $2.24 (prior $2.43).
Needham: Ciena reported mixed fiscal second-quarter results, with revenue and adjusted EPS +3% and -10 cents versus consensus, and fiscal second-half guidance reflects meaningfully higher revenue growth but lower gross margin and EPS than expected.
Fiscal second-quarter strength in Cloud (+88% Y/Y) drove the outperformance and strong bookings (B2B &gt; 1), but new products that carry lower gross margins are increasing in mix faster than expected, the analyst said. 
Increased tariff costs also impact gross profit by ~$10 million per quarter, which he feared could worsen given uncertainties.
Koontz noted the stock pullback as a buying opportunity for a company with the industry&#8217;s best technology and customer relationships. The analyst expects Ciena to benefit from continued share gains and is enthused about emerging intra-data center opportunities in fiscal 2027, although less bullish on Switching and Broadband.
Koontz projected fiscal 2025 revenue of $4.57 billion (prior $4.44 billion) and adjusted EPS of $2.25 (prior $2.58).
CIEN Price Action: CIEN stock is up 0.22% at $73.29 at publication on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="http://benzinga.com/markets/25/06/45785351/which-internet-software-stocks-is-jp-morgan-bullish-on" target="_blank" rel="noreferrer noopener">Which Internet Software Stocks Is JP Morgan Bullish On?</a> Photo: Michael Vi via Shutterstock</li>
</ul>

Reiteration

Tech

ADTN

CIEN

COHR

LITE

RBBN

VIAV

Ciena Poised For Growth On Cloud Demand, But Analysts Warn About Margin Pressure, Tariff Costs

AMTX

Aemetis shares are trading higher after Ascendiant Capital maintained its Buy rating on the stock and raised the price target from $19 to $20.

Shares of Recursion Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict molecular binding affinity with <a href="https://www.benzinga.com/pressreleases/25/06/g45814396/mit-and-recursion-release-boltz-2-next-generation-ai-model-to-predict-binding-affinity-at-unpreced">unmatched speed and accuracy. </a>
What To Know: The model, which outperforms previous tools including AlphaFold3 and Recursion's own Boltz-1, is built to advance drug discovery by significantly accelerating early-stage molecular screening.
Boltz-2 is the first biomolecular foundation model to jointly predict molecular structure and binding affinity in a single framework. It approaches the precision of traditional physics-based free energy perturbation calculations while operating up to 1,000 times faster. This drastic increase in efficiency makes large-scale virtual screening more practical, reducing costs and removing a key bottleneck in identifying viable drug candidates.
The model was trained on Recursion's NVIDIA-powered BioHive-2 supercomputer and incorporates roughly five million binding affinity measurements. It also introduces more realistic simulations and greater control features for researchers. Recursion emphasized that the tool is fully open-source under an MIT license, allowing academic and commercial teams alike to use and adapt it freely.
The strong market reaction reflects investor optimism that Boltz-2 will give Recursion a competitive edge in the pharmaceutical AI space, where speed and predictive power are crucial for drug development success. The collaboration with MIT also reinforces Recursion's position at the intersection of advanced computing and biomedical research.
RXRX Price Action: Recursion Pharmaceuticals shares were up 18.4% at $5.41 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li>Stocks Rally On Strong Jobs Numbers; Tesla Rebounds As Trump-Musk Feud Softens: What&#8217;s Driving Markets Friday?</li>
</ul>
Image Via Shutterstock.

Recursion Pharmaceuticals Stock Surges On Breakthrough AI Model Launch With MIT

As global growth forecasts dim and trade tensions rattle markets, <a href="https://www.benzinga.com/money/best-dividend-stocks-to-buy-and-hold">high-dividend stocks</a> are stealing the spotlight. The OECD just <a href="https://www.benzinga.com/markets/equities/25/06/45752680/global-growth-forecast-cut-taco-and-blind-money-support-the-stock-market">slashed its U.S. GDP outlook</a> to 1.6% for 2025 from 2.2%, citing persistent policy uncertainty and trade friction. 
That's prompted investors to sharply pivot toward dividend payers—names that offer predictable income when price action gets erratic.
In an environment where the S&amp;P 500 <a href="https://www.multpl.com/s-p-500-dividend-yield/table/by-year">yields</a> a tepid 1.28%, cash-generating stalwarts with robust balance sheets and fat dividends are in high demand. Historically, dividend-paying stocks have outpaced non-payers by more than 2x in average annual returns, and June 2025 is shaping up to be no exception.
Read Also: <a href="https://www.benzinga.com/Opinion/25/06/45754902/under-the-radar-why-low-profile-dividend-stocks-could-be-your-best-asset">Under the Radar: Why Low-Profile Dividend Stocks Could Be Your Best Asset</a>
Here are three high-yield stocks &#8211; and one ETF &#8211; that are standing out in this market:
<h2 class="wp-block-heading">Realty Income Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) – Yield: 5.77%</h2>
The monthly payout machine continues to deliver, with 659 straight dividend checks and a rock-solid 75% AFFO payout ratio. 
Realty Income's <a href="https://www.realtyincome.com/sites/realty-income/files/2025-05/Quarterly_Investor_Presentation-Q1_2025.pdf">$23 billion</a> in first-quarter acquisition opportunities and A-rated credit make it a defensive pick as tariff negotiations linger.
<h2 class="wp-block-heading">Enterprise Products Partners LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) – Yield: 6.89%</h2>
Energy's volatility hasn't fazed this pipeline operator. Its fee-based model and <a href="https://ir.enterpriseproducts.com/news-releases/news-release-details/enterprise-reports-first-quarter-2025-earnings">$6 billion</a> in 2025 projects support a generous yield, without the commodity price drama. A steady cash-flow engine for income seekers.
<h2 class="wp-block-heading">OneMain Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMF#NYSE">OMF</a>) – Yield: 8.02%</h2>
With a 9.69% gain over the past month alone, OneMain Holdings blends high yield with capital appreciation. Its strong balance sheet gives investors confidence amid uncertain economic signals.
<h2 class="wp-block-heading">Schwab U.S. Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>) – Yield: 3.96%</h2>
Prefer a hands-off approach? 
SCHD offers a diversified path to income with a 4% yield and holdings boasting 8.4% dividend growth over the past five years. It's a popular pick for those avoiding stock-specific risk.
As markets climb but face lingering macro uncertainty, income-focused strategies are staging a strong comeback. For investors looking to shield their portfolios while still collecting steady cash, these dividend leaders offer exactly that &#8211; without needing to call the market&#8217;s next move.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/45811222/wall-streets-most-accurate-analysts-give-their-take-on-3-financial-stocks-with-over-15-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Financial Stocks With Over 15% Dividend Yields</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Dividends

SCHD

High-Yield Stocks Flex Muscle As Growth Outlook Fades: 4 Dividend Plays To Watch In June

Know Labs Shares Resume Trade Following Circuit Breaker Halt

Rocket Lab Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) shares are trading higher Friday after the company announced the launch window for <a href="https://www.benzinga.com//node/45758874">its next mission</a>, &#8216;The Mountain God Guards,&#8217; for the Institute for Q-shu Pioneers of Space, Inc.
What To Know: Rocket Lab announced that the mission will launch from New Zealand during a launch window that opens on June 10, 2025 UTC.
The satellite is named QPS-SAR-11 (also known as YAMATSUMI-I) will join the iQPS network, where it will help capture detailed images of Earth and support global monitoring efforts.
The mission is part of Rocket Lab's ramped-up launch schedule for Electron, the world's most frequently launched small orbital rocket. It marks the company's third Electron launch in 24 days, the 66th Electron launch overall and the fourth dedicated mission for the iQPS satellite network.
"The Mountain God Guards" will also be Rocket Lab's eighth mission of 2025.
Related Link: <a href="https://www.benzinga.com/markets/large-cap/25/06/45814068/novo-nordisks-wegovy-tied-to-increased-risk-of-rare-vision-loss-disorder-european-regulators-say">Novo Nordisk&#8217;s Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say</a>
RKLB Price Action: At the time of writing, Rocket Lab shares are trading 8.11% higher at $28.62, according to data from Benzinga Pro.
Image: via Shutterstock

RKLB

Rocket Lab Stock Is Moving Higher Friday: What's Going On?

ADXN

Addex Therapeutics shares are trading higher after the company reported its preclinical results for GABAB PAM.

Press Releases

Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results

Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences

Earnings

Certara Reports Fourth Quarter 2024 Financial Results

Management

Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities

Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

Certara to Participate in Upcoming Investor Conferences

Certara Reports First Quarter 2025 Financial Results

Small Cap

Opinion

AI Could Add $461 Billion to Global Healthcare--And These New Platforms Are Leading the Charge

Comments

Certara

Certara (CERT) 옵션

Certara (NASDAQ:CERT) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌